Trial Information
C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment
Inclusion Criteria:
- at least 20 years of age
- previously untreated
- complete pre-treatment clinical staging including bone marrow examination
- written informed consent to participate in the study
Exclusion Criteria:
- concurrent active malignant tumor(s)
- pregnant or breast feeding women
- non-compliant to PET/CT or to MRI
- marked renal impairment (contraindicated for contrast-enhanced MRI)
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic
Outcome Measure:
Pretreatment lesion detection
Outcome Description:
Reference standards: bone marrow examination and whole-body dynamic contrast-enhanced MRI
Outcome Time Frame:
Within 2 weeks before initiation of therapy
Safety Issue:
No
Principal Investigator
Chieh Lin, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Department of Molecular Imaging Center and Nuclear Medicine, Chang Gung Memorial Hospital
Authority:
Taiwan: Department of Health
Study ID:
99-2177A
NCT ID:
NCT01691300
Start Date:
May 2011
Completion Date:
December 2015
Related Keywords:
- Multiple Myeloma
- C11-acetate PET/CT
- Multiple myeloma
- Pretreatment staging
- Response assessment
- Multiple Myeloma
- Neoplasms, Plasma Cell